“The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills.”
(PRWEB) October 27, 2011
The Consumer Justice Foundation, a team of consumer advocates who dedicate their time to providing free online resources to consumers who need information regarding dealing with large corporations such as insurance companies and the risks associated with pharmaceutical drugs, hereby alerts the public to a December 8, 2011 FDA meeting that includes Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee in order to discuss the benefits and risks of drospirenone-containing oral contraceptives. These contraceptives include brand names Yaz and Yasmin. The announcement came via the Federal Register Volume 76, Number 185 (Friday, September 23, 2011), Pages 59143-59144, FR Doc No: 2011-24532.
Specifically, the FDA stated in a Safety Communication on September 26 that appears on its Web site that the agency “remained concerned” about the potential increase in risks for women who use these medications of developing blood clots that could in some cases prove to be fatal. Over time, Yaz, Yasmin and other birth control medications containing drospirenone have been linked to side effects that include DVT, or deep vein thrombosis, pulmonary embolisms, heart attacks and strokes. Specifically, the FDA stated, “The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills.”
This announcement of this December 8 joint meeting from the FDA comes on the heels of reviewing a study that indicated that women who used any of these birth control medications faced a 1.5 times greater chance of developing these types of blood clots than those women who did not use them. However, this study also conflicts with other studies that have concluded the lack of the existence of Yaz or Yasmin side effects.
As a result of this conflicting information, the FDA has scheduled this joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8, 2011. This meeting will be in part held to move towards some sort of conclusion regarding the safety of these birth control medications.
About the Consumer Justice Foundation
The Consumer Justice Foundation, whose Web site can be found at http://www.consumerjusticefoundation.com, is a for-profit organization that serves two purposes for consumers: (1) to provide educational information regarding the policies and procedures of large corporations and how they affect the average consumer; and (2) to provide news updates and resources that continue to update consumers regarding developments taken by corporations that include pharmaceutical drug companies, auto manufacturers and insurance companies so that consumers who have been harmed can use these informational resources to connect to an experienced professional who can help them. The team at the Consumer Justice Foundation is staffed by experienced and passionate consumer advocates whose mission is to raise the awareness of issues that could pose a risk of harm to those who may not otherwise be aware of the dangers they face.